Acceleron Investors Want Merck To Pay More, Ask Company To Wait For Better Offer

$11.5bn Acquisition Values Firm At A 34%-38% Premium

 
• By Mandy Jackson
  
Hand turns a dice and changes the expression "bad deal" to "good deal"
Three investors said they will not sell their Acceleron shares to Merck • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business